IBDEI39Q ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,54926,1,3,0)
 ;;=3^Carcinoma in Situ of Endocervix
 ;;^UTILITY(U,$J,358.3,54926,1,4,0)
 ;;=4^D06.0
 ;;^UTILITY(U,$J,358.3,54926,2)
 ;;=^5001938
 ;;^UTILITY(U,$J,358.3,54927,0)
 ;;=D06.1^^256^2775^41
 ;;^UTILITY(U,$J,358.3,54927,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54927,1,3,0)
 ;;=3^Carcinoma in Situ of Exocervix
 ;;^UTILITY(U,$J,358.3,54927,1,4,0)
 ;;=4^D06.1
 ;;^UTILITY(U,$J,358.3,54927,2)
 ;;=^5001939
 ;;^UTILITY(U,$J,358.3,54928,0)
 ;;=D06.7^^256^2775^39
 ;;^UTILITY(U,$J,358.3,54928,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54928,1,3,0)
 ;;=3^Carcinoma in Situ of Cervix,Other Parts
 ;;^UTILITY(U,$J,358.3,54928,1,4,0)
 ;;=4^D06.7
 ;;^UTILITY(U,$J,358.3,54928,2)
 ;;=^5001940
 ;;^UTILITY(U,$J,358.3,54929,0)
 ;;=D04.9^^256^2775^42
 ;;^UTILITY(U,$J,358.3,54929,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54929,1,3,0)
 ;;=3^Carcinoma in Situ of Skin
 ;;^UTILITY(U,$J,358.3,54929,1,4,0)
 ;;=4^D04.9
 ;;^UTILITY(U,$J,358.3,54929,2)
 ;;=^5001925
 ;;^UTILITY(U,$J,358.3,54930,0)
 ;;=C91.11^^256^2775^45
 ;;^UTILITY(U,$J,358.3,54930,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54930,1,3,0)
 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,In Remission
 ;;^UTILITY(U,$J,358.3,54930,1,4,0)
 ;;=4^C91.11
 ;;^UTILITY(U,$J,358.3,54930,2)
 ;;=^5001766
 ;;^UTILITY(U,$J,358.3,54931,0)
 ;;=C91.10^^256^2775^46
 ;;^UTILITY(U,$J,358.3,54931,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54931,1,3,0)
 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,Not in Remission
 ;;^UTILITY(U,$J,358.3,54931,1,4,0)
 ;;=4^C91.10
 ;;^UTILITY(U,$J,358.3,54931,2)
 ;;=^5001765
 ;;^UTILITY(U,$J,358.3,54932,0)
 ;;=C92.11^^256^2775^47
 ;;^UTILITY(U,$J,358.3,54932,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54932,1,3,0)
 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,In Remission
 ;;^UTILITY(U,$J,358.3,54932,1,4,0)
 ;;=4^C92.11
 ;;^UTILITY(U,$J,358.3,54932,2)
 ;;=^5001793
 ;;^UTILITY(U,$J,358.3,54933,0)
 ;;=C92.10^^256^2775^48
 ;;^UTILITY(U,$J,358.3,54933,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54933,1,3,0)
 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,Not in Remission
 ;;^UTILITY(U,$J,358.3,54933,1,4,0)
 ;;=4^C92.10
 ;;^UTILITY(U,$J,358.3,54933,2)
 ;;=^5001792
 ;;^UTILITY(U,$J,358.3,54934,0)
 ;;=D47.1^^256^2775^49
 ;;^UTILITY(U,$J,358.3,54934,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54934,1,3,0)
 ;;=3^Chronic Myeloproliferative Disease
 ;;^UTILITY(U,$J,358.3,54934,1,4,0)
 ;;=4^D47.1
 ;;^UTILITY(U,$J,358.3,54934,2)
 ;;=^5002256
 ;;^UTILITY(U,$J,358.3,54935,0)
 ;;=C82.69^^256^2775^50
 ;;^UTILITY(U,$J,358.3,54935,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54935,1,3,0)
 ;;=3^Cutaneous Follicle Center Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,54935,1,4,0)
 ;;=4^C82.69
 ;;^UTILITY(U,$J,358.3,54935,2)
 ;;=^5001530
 ;;^UTILITY(U,$J,358.3,54936,0)
 ;;=C82.60^^256^2775^51
 ;;^UTILITY(U,$J,358.3,54936,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54936,1,3,0)
 ;;=3^Cutaneous Follicle Center Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,54936,1,4,0)
 ;;=4^C82.60
 ;;^UTILITY(U,$J,358.3,54936,2)
 ;;=^5001521
 ;;^UTILITY(U,$J,358.3,54937,0)
 ;;=D56.2^^256^2775^52
 ;;^UTILITY(U,$J,358.3,54937,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54937,1,3,0)
 ;;=3^Delta-Beta Thalassemia
 ;;^UTILITY(U,$J,358.3,54937,1,4,0)
 ;;=4^D56.2
 ;;^UTILITY(U,$J,358.3,54937,2)
 ;;=^340496
 ;;^UTILITY(U,$J,358.3,54938,0)
 ;;=D75.9^^256^2775^53
 ;;^UTILITY(U,$J,358.3,54938,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54938,1,3,0)
 ;;=3^Disease of Blood/Blood-Forming Organs,Unspec
 ;;^UTILITY(U,$J,358.3,54938,1,4,0)
 ;;=4^D75.9
